Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO)

Q: What does CUSIP 36322Q107 represent in this 13F holders report?

CUSIP 36322Q107 is the security identifier for GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value used to aggregate holder disclosures.

Q: How many institutions held GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value in Q1 2024?

24 institutional investors reported GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 36322Q107

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
Total 13F shares: 3,955,560
Total 13F value: $3,086,219
Share change: +98,356
Put/Call ratio: 0.65%
SEC-reported price per share: $0.78
Number of holders: 24
Value change: +$84,662
Number of buys: 12
Number of sells: 6
Shares outstanding: 7,500,000

Security key

36322Q107

Report period

Q1 2024

Institutions

Top holders

GLTO full security history Ownership snapshot Full 13F holder table Chemomab Therapeutics Ltd. SEC filings Chemomab Therapeutics Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

OrbiMed Israel GP Ltd.

Disclosed value leader

OrbiMed Israel GP Ltd.

Comparable rows

0/15

Latest evidence

31 Dec 2023

3/4/5 13F Highest disclosed value: $10,108,146 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

OrbiMed Israel GP Ltd. has the largest disclosed position value at $10.11M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens OrbiMed Israel GP Ltd.'s linked filing trail.

Disclosed position value Top 5

OrbiMed Israel GP Ltd. $10.11M

Novo Holdings A/S $1.8M

ORBIMED ADVISORS LLC $1.14M

RENAISSANCE TECHNOLOGIES LLC $293K

VANGUARD GROUP INC $159.3K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
OrbiMed Israel GP Ltd.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$10,108,146 2,241,274 shares	—	03 Jan 2023
Novo Holdings A/S	13F Company 13F	— denominator unverified	$1,798,410 2,497,791 shares	—	31 Dec 2023
ORBIMED ADVISORS LLC	13F Company 13F	— denominator unverified	$1,143,050 2,241,274 shares	—	31 Dec 2023
RENAISSANCE TECHNOLOGIES LLC	13F Company 13F	— denominator unverified	$293,000 406,968 shares	—	31 Dec 2023
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$159,264 221,200 shares	—	31 Dec 2023
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	— mixed-class rows	$156,014 220,070 shares mixed-class rows	—	31 Dec 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

3,955,560

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q1 2024 value	Q1 2024 value	Value change	Value Chg %